DAFTAR PUSTAKA

1. Collins MT, Singer FR, Eugster E. McCune-Albright syndrome and the

extraskeletal manifestations of fibrous dysplasia. Orphanet Journal of Rare Disease
2012;7(Suppl 1):S4.
2. Collins MT, Sarlis NJ, Merino MJ, Monroe J, Crawford SE, Krakoff JA, et al.
Thyroid carcinoma in the McCune-Albright syndrome: contributory role of
activating Gs alpha mutations. J Clin Endocrinol Metab. 2003;88:4413-4417.
3. Eugster EA, Shankar R, Feezle LK, Pescovitz OH. Tamoxifen Treatment of
Progressive Precocious Puberty in a Patient with McCune-Albright Syndrome.
Journal of Pediatric Endocrinology and Metabolism 199;12:681-686.
4. Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH, et al.
Tamoxifen treatment for precociuos puberty in McCune-Albright syndrome : a
multicenter trial. J Pediatr. 2003;143:60-6.
5. Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet Journal of
Rare Disease 2008;3:12.
6. Siadati S, Shafigh E. McCune-Albright syndrome: A case report. Iranian Medicine
2010;13(3):245-247.
7. Haghighatafshar M, Esfahani AF, Karami F, Saghari M, Fallahi B, Beiki D, et al.
McCune-Albright syndrome: Report of a case. Iran J Nucl Med. 2010;18(1):57-61.
8. Feuillan PP: McCune-Albright syndrome. Curr Ther Endocrinol Metab.
1997;6:235-239.
9. Defilippi C, Chiappetta D, Marzari D, Mussa A, Lala R: Image diagnosis in
McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2006;19(Suppl 2):561-
570.
10. Tanabeu Y, Nakahara S, Mitsuyama S, Ono M, Toyoshima S: Breast cancer in a
patient with McCune-Albright syndrome. Breast Cancer 1998;5:175-178.
11. Shenker A, Weinstein LS, Moran A, Pescovitz OH, Charest NJ, Boney CM et al.
Severe endocrine and nonendocrine manifestations of the McCune-Albright
syndrome associated with activating mutations of stimulatory G protein GS. J
Pediatr. 1993;123(4):509-518.
12. Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural
growth. Hum Reprod Update 2004;10(2):135-147.
13. Brown RJ, Kelly MH, Collins MT. Cushing syndrome in the McCune-Albright
Syndrome. J Clin Endocrinol Metab 2010; 95: 1508-15.
14. Leet AI, Chebli C, Kushner H, Chen CC, Kelly MH, Brillante BA et al. Fracture
incidence in polyostotic fibrous dysplasia and McCune-Albright syndrome. J Bone
Miner Res 2004; 19: 571-7.
15. Benhamou J, Gensburger D, Messiaen C, Chapurlat R. Natural history and
prognostic factor of fibrous displasia of bone in a modern cohort of 372 patients-the
francedys study. Bone Abstract 2016; 5: 419.
16. Morinsky DE, Muntner P. Medication adherence scale versus pharmacy fill rates in
senior with hypertension. Am J Manag Care 2009;15(1):59-66.
17. Departemen Kesehatan RI. Pedoman teknis penilaian rumah sehat. Jakarta: Ditjen
PPM dan PL; 2005
18. Vami JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the pediatric
quality of life inventory version 4.0 generic core scales in healthy and patient
populations. Med Care 2001;39(8):800-812.
19. Völkl TM, Dörr HG. McCune-Albright syndrome: clinical picture and natural
history in children and adolescents. J Pediatr Endocrinol Metab. 2006;19:551-559.
20. Mieszczak J, Eugster EA. Treatment of precocius puberty in McCune-Albright
syndrome. Ped Endocrinol. 2007;4:419-422.
21. Matarazzo P, Lala R, Andreo M, Einauidi S, Altare F, Viora E, et al. McCune-
Albright syndrome: persistence of autonomous ovarian hyperfunction during
adolesance and early adult age. J Pediatr Endocrinol Metab 2006;19:607-617.
22. Nunez S, Calis K, Cutler G, Jones J, Feuillan P. Lack of efficicacy of fadrazole in
treating precocius puberty in girls with the McCune- Albright syndrome. J Clin
Endocrinol Metab. 2003;88:5730-5733.
23. Feuillan P, Foster C, Pescovitz O, Hench K, Shawker T, Dwyer A, et al. Treatment
of precocious puberty in the McCune - Albright with the aromatase inhibitor
testolactone. N EngJ Med. 1986;315:1115-1119.
24. Feuillan PP, Jones J, Cutler GB. Long term testolactone therapy for precocious
puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab.
1993;77(3):647-651.
25. Feuillan P, Calis P, Hill S, Shawker T, Robey P, Collins M. Letrazole treatment of
precocious puberty in girls with the McCune-Albright syndrome: a pilot study. J
Clin Endocrinol Metab. 2007;92:2100-2106.
26. Estrada A, Boyce AM, Brillante BA, Guthrie LC, Gafni RI, Collins MT. Long-term
outcomes of letrozole treatment for precocious puberty in girls with McCune-
Albright syndrome. To be publish in Eur J Endocrinol [Preprint] 2016. Available
from: http://dx.doi.org/10.1530/EJE-16-0526.
27. Aycan Z, Onder A, Cetinkaya S. Eight-year follow-up of a girl with McCune-
Albright syndrome. J Clin Res Ped Endo. 2011;3(1):40-42.
28. Posner, R.B. Early menarche: a review of research on trends in timing, racial
differences, etiology and psychosocial consequences. Journal of Sex Roles 2006;
54: 315–322.
29. Ge X, Brody GH, Conger RD, & Simons RL. Pubertal maturation and african
american children's internalizing and externalizing symptoms. Journal of Youth and
Adolescence 2006;35(4): 528-537.
30. Natsuaki MN, Leve LD, Mendle J. Going through the rites of passage: timing and
transition of menarche, childhood sexual abuse, and anxiety symptoms in girls.
Journal of Youth Adolescence 2011; 40:1357–1370.
31. Marv´an ML, Morales C, Iniestra SC . Emotional reactions to menarche among
mexican women of different generations. Journal of Sex Roles 2006:54;323–330.
32. Sarafino EP. Health psychology: biopsychosocial interaction. Edisi ketiga. New
York: John Wiley & Sons Inc;1998.